574 related articles for article (PubMed ID: 27488859)
1. Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting.
Ueno T; Koiwaya H; Sasaki KI; Katsuki Y; Katsuda Y; Murasato Y; Shimamatsu J; Umeji K; Otsuka Y; Kawasaki T; Shibata Y; Fukumoto Y
Cardiovasc Interv Ther; 2017 Oct; 32(4):341-350. PubMed ID: 27488859
[TBL] [Abstract][Full Text] [Related]
2. Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation.
Shimamatsu J; Sasaki KI; Katsuki Y; Kawasaki T; Murasato Y; Ajisaka H; Yokoi H; Tashiro H; Harada A; Hirakawa Y; Ishizaki Y; Ishimatsu T; Kagiyama K; Fukumoto Y; Kakuma T; Ueno T
Heart Vessels; 2020 Mar; 35(3):312-322. PubMed ID: 31549178
[TBL] [Abstract][Full Text] [Related]
3. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease.
Nishi T; Ariyoshi N; Nakayama T; Fujimoto Y; Sugimoto K; Takahara M; Wakabayashi S; Koshizaka M; Hanaoka H; Kobayashi Y
Circ J; 2015; 79(11):2439-44. PubMed ID: 26310876
[TBL] [Abstract][Full Text] [Related]
4. Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study.
Nakamura M; Isshiki T; Kimura T; Ogawa H; Yokoi H; Nanto S; Takayama M; Kitagawa K; Ikeda Y; Saito S
Int J Cardiol; 2015 Mar; 182():541-8. PubMed ID: 25679803
[TBL] [Abstract][Full Text] [Related]
5. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
[TBL] [Abstract][Full Text] [Related]
6. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
[TBL] [Abstract][Full Text] [Related]
7. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
Ozawa T; Suda M; Ikegami R; Takano T; Wakasugi T; Yanagawa T; Tanaka K; Ozaki K; Hirono S; Minamino T
Int Heart J; 2018 Jan; 59(1):21-26. PubMed ID: 29279531
[TBL] [Abstract][Full Text] [Related]
8. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
Kitano D; Takayama T; Fukamachi D; Migita S; Morikawa T; Tamaki T; Kojima K; Mineki T; Murata N; Akutsu N; Sudo M; Hiro T; Hirayama A; Okumura Y
Catheter Cardiovasc Interv; 2020 Jan; 95(1):E8-E16. PubMed ID: 30983087
[TBL] [Abstract][Full Text] [Related]
9. Time course of the antiplatelet effect after switching to clopidogrel from initial prasugrel therapy in patients with acute coronary syndrome.
Furuse E; Takano H; Yamamoto T; Kubota Y; Yoshizane T; Kitamura M; Miyachi H; Hosokawa Y; Shimizu W
Heart Vessels; 2017 Dec; 32(12):1432-1438. PubMed ID: 28685204
[TBL] [Abstract][Full Text] [Related]
10. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
Doll JA; Neely ML; Roe MT; Armstrong PW; White HD; Prabhakaran D; Winters KJ; Duvvuru S; Sundseth SS; Jakubowski JA; Gurbel PA; Bhatt DL; Ohman EM; Fox KAA;
J Am Coll Cardiol; 2016 Mar; 67(8):936-947. PubMed ID: 26916483
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
[TBL] [Abstract][Full Text] [Related]
12. Comparison of platelet aggregation response in switching regimen from prasugrel to clopidogrel between CYP2C19 extensive versus non-extensive metabolizers.
Ebisawa S; Ueki Y; Mochidome T; Senda K; Nishimura H; Saigusa T; Miura T; Motoki H; Koyama J; Ikeda U
Cardiovasc Interv Ther; 2018 Jul; 33(3):277-284. PubMed ID: 28681220
[TBL] [Abstract][Full Text] [Related]
13. Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome.
Collet JP; Kerneis M; Hulot JS; O'Connor SA; Silvain J; Mansencal N; Brugier D; Abtan J; Barthélémy O; Vignalou JB; Payot L; Rousseau H; Vicaut E; Montalescot G;
Thromb Haemost; 2016 Jan; 115(2):382-91. PubMed ID: 26423110
[TBL] [Abstract][Full Text] [Related]
14. Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
Kudaravalli M; Althouse AD; Marroquin OC; Khandhar SJ; Sharbaugh MS; Toma C; Conrad Smith AJ; Schindler JT; Lee JS; Mulukutla SR
Int J Cardiol; 2016 Nov; 223():854-859. PubMed ID: 27592042
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
[TBL] [Abstract][Full Text] [Related]
16. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.
González A; Moniche F; Cayuela A; García-Lozano JR; Torrecillas F; Escudero-Martínez I; Gonzalez-Marcos JR; Mayol A; Montaner J
Eur J Vasc Endovasc Surg; 2016 Feb; 51(2):175-86. PubMed ID: 26526111
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
[TBL] [Abstract][Full Text] [Related]
19. Impact of dual antiplatelet therapy with adjusted-dose prasugrel on mid-term vascular response in patients undergoing elective percutaneous coronary intervention with everolimus-eluting stents.
Toba T; Shinke T; Otake H; Sugizaki Y; Takeshige R; Onishi H; Nagasawa A; Tsukiyama Y; Yanaka K; Nagano Y; Yamamoto H; Kawamori H; Matsuura A; Ishihara T; Matsumoto D; Igarashi N; Hayashi T; Yasaka Y; Kadotani M; Fujii T; Shite J; Okada M; Sakakibara T; Hirata KI
Heart Vessels; 2019 Jun; 34(6):936-947. PubMed ID: 30599059
[TBL] [Abstract][Full Text] [Related]
20. Optimal Same-Day Platelet Inhibition in Patients Receiving Drug-Eluting Stents With or Without Previous Maintenance Thienopyridine Therapy: from the Evaluation of Platelet Inhibition in Patients Having A VerifyNow Assay (EPIPHANY) Trial.
Lee MS; Shlofmitz E; Haag E; Santiago L; Pollack S; Reichek N; Shlofmitz RA
Am J Cardiol; 2017 Apr; 119(7):991-995. PubMed ID: 28159194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
